<DOC>
	<DOCNO>NCT00213057</DOCNO>
	<brief_summary>The primary aim study assess safety acceptability Carraguard apply vaginally prior sexual intercourse six month woman men ; examine several dimension acceptability . Secondary aim gauge reaction non-contraceptive microbicide , ass use dynamic among Thai couple observe preliminary indication sexually transmit infection reproductive tract infection avert . The hypothesis Carraguard would cause little significant irritation , include lesion ; woman men would find Carraguard acceptable .</brief_summary>
	<brief_title>Safety Acceptability Carraguard™ Among HIV-Negative Couples Thailand</brief_title>
	<detailed_description>Carraguard™ ( PC-515 ) , Population Council ’ lead candidate microbicide , test triple-masked , randomize , placebo-controlled trial field one site Chiang Rai , northern Thailand . The primary aim study assess Carraguard ’ safety ( toxicity ) men woman – include sign local irritation , itch burning ; change vaginal flora ( woman ) ; incidence abnormal external genital , vaginal ( woman ) , cervical finding ( woman ) – apply vaginally prior intercourse 6 month ; evaluate acceptability ; gauge men ’ woman ’ reaction non-contraceptive microbicide ; explore microbicide use dynamic Thai population . Secondary aim investigate sexually transmit infection avert – include HIV , C. trachomatis , N. gonorrhoeae , T. vaginalis , T. pallidum ( preliminary indication ) men woman ; bacterial vaginosis candidaisis woman ; balanitis men ; effect cervical cytology .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Syphilis</mesh_term>
	<mesh_term>Gonorrhea</mesh_term>
	<mesh_term>Trichomonas Infections</mesh_term>
	<mesh_term>Trichomonas Vaginitis</mesh_term>
	<criteria>· In good health , Aged 18 year old , Resident least 1 year ; plan stay least 12 month , HIVseronegative free STD initial screening exam , No report sex partner current partner prior year plan sex partner duration study , Not use condom routinely ( &gt; 25 % time ) prior year Willing able comply study protocol ( include test HIV , learn result , agree partner notification curable STD diagnose , undergo clinical evaluation ) , Able achieve score 80 % good truefalse test key study concept , Able give inform consent . Planning vaginal sexual intercourse together average least per week next six month . · Pregnant desire become pregnant time study participation , Delivered abort pregnancy within six week prior screen , Male sex partner know enrollment HIV positive , History surgery external genitalia , vagina cervix six week prior screen , Recent history nonmenstrual vaginal bleeding intercourse , Clinically detectable genital abnormality ( include presence wart , structural congenital abnormality ) , Genital epithelial disruption ; men/women heal lesion ( intact epithelium ) eligible , Untreated symptomatic bacterial vaginosis candidiasis . Women asymptomatic BV yeast may enrol . Women treat symptomatic BV candidaisis may enrol long symptomatic . Women sign laboratory evidence BV candidaisis may enrol asymptomatic . Women symptoms vaginal infection may enrol enrollment visit stat laboratory evaluation negative BV , candidaisis trichomoniasis , Presence balanitis . Men resolve balanitis ( e.g . treatment ) eligible , Abnormal Pap smear ( Class II ) , History sensitivity/allergy latex , Concurrent participation another trial vaginal product , Injection recreational drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2002</verification_date>
	<keyword>Microbicides</keyword>
	<keyword>HIV prevention</keyword>
	<keyword>sexually transmit infection</keyword>
	<keyword>carrageenan</keyword>
	<keyword>sero-concordant couple</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV</keyword>
</DOC>